Viral-vector vaccines ‘likely best with rituximab’
Researchers recommend COVID-19 vaccines associated with low release of interferon for B cell-depleted patients
In patients treated with rituximab, adenovirus-based vaccines that don’t induce a type 1 interferon (IFN-I) response will likely enable a better T-cell immune response than mRNA vaccines, German researchers suggest.
Their hypothesis is based on their studies of an influenza vaccine in people with RA, as well as other vaccines in mice, and has not yet been tested in patients being vaccinated against the SARS-CoV-2 virus, although clinical trials are planned.
